European Primary Care Cardiovascular Society

Lipids

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

New cholesterol guidelines: aim therapy at patients at highest risk who will benefit most

3' education - Nov. 22, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

Lipids and food

10' education - July 11, 2018 - Prof. David Marais - Cape Town, South Africa

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

How do the latest guideline changes affect management of dyslipidaemia in primary care?

10' education - May 26, 2017

What is the evidence base for lipid modification in the guidelines updates?

10' education - Feb. 24, 2016 - Prague - EPCCS 2015

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Cholesterol guideline breaking news in USA

3' education - Dec. 16, 2013 - AHA 2013 - Clyde Yancy

In 75-year-olds on statin for primary prevention, stopping therapy was associated with higher CV risk

Literature - Aug. 13, 2019 - Giral P et al.,
Observational population-based study suggests that continuing statin therapy after the age of 75 years may reduce CV risk in persons taking the medication for primary prevention.

Observational population-based study suggests that continuing statin therapy after the age of 75 years may reduce CV risk in persons taking the medication for primary prevention.

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD
Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

Lowering remnants becomes more important, also in light of the obesity epidemic

EAS 2019 - Maastricht, The Netherlands

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard
Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Lipid-lowering drug prescription decreases with age but increases with frailty

Literature - June 18, 2019 - Kleipool EEF et al. - Age and Ageing 2019

Based on a large Dutch primary care database, lipid-lowering treatment declined with increasing age in subjects aged ≥70 years, with higher prescription in frail vs. non-frail older adults regardless of CVD at baseline.

Clinical interest in HDL is historically low, but continued research into HDL yields interesting results

News - May 30, 2019
Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

Analysis of 4S data suggest greater benefit of statin therapy in those with inherited high LDL

News - May 29, 2019
An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

EAS 2019 An analysis of the 4S trial data suggests that people with characteristics suggestive of FH, gain greater clinical benefit from statin therapy, in reducing events and mortality.

Individuals with probable FH but no diagnosis have worse survival compared with those with an FH diagnosis

News - May 31, 2019
A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

EAS 2019 A UK study involving over 1.7 million health records in the general population suggests that a considerable number of people may have FH but are not diagnosed yet, leading to premature mortality

Lowering of LDL-c with fixed combination of two non-statin cholesterol-lowering agents in high-risk patients

News - June 7, 2019
A fixed combination of bempedoic acid and ezetimibe lowered LDL-c at 12 weeks more than with the individual components, in high-risk patients not at LDL-c goal.

EAS 2019 A fixed combination of bempedoic acid and ezetimibe lowered LDL-c at 12 weeks more than with the individual components, in high-risk patients not at LDL-c goal.

Little attention for remnants in recent decades, unrightful so

News - June 7, 2019
Børge Nordestgaard made the case for remnant cholesterol and TG, because of the known links of high levels with heart attack, ischemic stroke and death, more so than high LDL-c.

EAS 2019 Børge Nordestgaard made the case for remnant cholesterol and TG, because of the known links of high levels with heart attack, ischemic stroke and death, more so than high LDL-c.

Higher CVD risk with sub-optimal LDL-c lowering in many patients initiating statin therapy

Literature - Apr. 29, 2019 - Akyea RK et al. - Heart 2019

In a primary care patient cohort, >50% of patients initiating statin therapy did not show optimal LDL-c lowering, which significantly increased their risk of future CVD events.

Inverse association between long-term statin adherence and all-cause mortality in ASCVD

Literature - Feb. 20, 2019 - Rodriguez F et al. - JAMA Cardiol 2019
A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

Efficacy of statins in primary CVD prevention confirmed in large meta-analysis, but individual benefit-harm profiles vary

Literature - Feb. 19, 2019 - Yebyo HG et al. - Am Heart J 2019

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.